These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 20304188

  • 1. Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus.
    Ayub-Ferreira SM, Avila MS, Feitosa FS, Souza GE, Mangini S, Marcondes-Braga FG, Issa VS, Bacal F, Chizzola PR, Cruz FD, Bocchi EA.
    Transplant Proc; 2010 Mar; 42(2):542-4. PubMed ID: 20304188
    [Abstract] [Full Text] [Related]

  • 2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 3. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 4. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 5. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 Sep; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus experience in heart transplantation.
    Aranda-Dios A, Lage E, Sobrino JM, Mogollón MV, Guisado A, Cabezón S, Hinojosa R, Hernández A, Ordóñez A.
    Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 8. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 9. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E, González-Costello J, Manito N, Roca J, Barbosa MJ, Nebot M, Salazar-Mendiguchia J, Berdejo J, Mañas P, Miralles A, Cequier A.
    Transplant Proc; 2012 Nov 27; 44(9):2564-6. PubMed ID: 23146455
    [Abstract] [Full Text] [Related]

  • 10. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.
    Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ.
    J Heart Lung Transplant; 2005 Nov 27; 24(11):1863-7. PubMed ID: 16297793
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
    Fernandez-Valls M, Gonzalez-Vilchez F, de Prada JA, Ruano J, Ruisanchez C, Martin-Duran R.
    Transplant Proc; 2005 Nov 27; 37(9):4021-3. PubMed ID: 16386615
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of sirolimus as rescue therapy in heart transplant recipients with renal failure: analysis of the Spanish Multicenter Observational Study (RAPACOR).
    Delgado JF, Crespo MG, Manito N, Camprecios M, Rábago G, Lage E, Arizón JM, Roig E.
    Transplant Proc; 2009 Nov 27; 41(9):3835-7. PubMed ID: 19917397
    [Abstract] [Full Text] [Related]

  • 13. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec 27; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 14. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 15. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 16. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Böger CA, Banas B, Obed A, Schlitt HJ, Krämer BK.
    Transplant Proc; 2007 Mar 27; 39(2):518-21. PubMed ID: 17362772
    [Abstract] [Full Text] [Related]

  • 17. Impact on renal function of the use of sirolimus in cardiac transplantation.
    Ubilla M, Mastrobuoni S, Cordero A, Castaño S, Herreros J, Rábago G.
    Transplant Proc; 2007 Sep 27; 39(7):2401-2. PubMed ID: 17889202
    [Abstract] [Full Text] [Related]

  • 18. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec 27; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 19. mTOR inhibitors: do they help preserve renal function?
    Moro J, Almenar L, Martínez-Dolz L, Agüero J, Rueda J, Arnau MA, Izquierdo M, Cano O, Sánchez-Lázaro I, Salvador A.
    Transplant Proc; 2007 Sep 27; 39(7):2135-7. PubMed ID: 17889116
    [Abstract] [Full Text] [Related]

  • 20. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients.
    Nair S, Eason J, Loss G.
    Liver Transpl; 2003 Feb 27; 9(2):126-9. PubMed ID: 12548505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.